| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6126971 | PHARMACIA | Stable oral CI-981 formulation and process for preparing same |
Jan, 2013
(11 years ago) | |
|
US6126971 (Pediatric) | PHARMACIA | Stable oral CI-981 formulation and process for preparing same |
Jul, 2013
(10 years ago) | |
| US5686104 | PHARMACIA | Stable oral CI-981 formulation and process of preparing same |
Nov, 2014
(9 years ago) | |
|
US5686104 (Pediatric) | PHARMACIA | Stable oral CI-981 formulation and process of preparing same |
May, 2015
(8 years ago) | |
| US5969156 | PHARMACIA | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jul, 2016
(7 years ago) | |
|
US5969156 (Pediatric) | PHARMACIA | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jan, 2017
(7 years ago) | |
| US6455574 | PHARMACIA | Therapeutic combination |
Aug, 2018
(5 years ago) | |
Caduet is owned by Pharmacia.
Caduet contains Amlodipine Besylate; Atorvastatin Calcium.
Caduet has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Caduet are:
- US6126971
- US6126971*PED
- US5686104
- US5686104*PED
- US5969156
- US5969156*PED
- US6455574
Caduet was authorised for market use on 29 July, 2004.
Caduet is available in tablet;oral dosage forms.
Caduet can be used as method of inhibiting cholesterol biosynthesis and treating hypercholesterolemia and method for treating hyperlipidemia, treatment of hypertension and hyperlipidemia with a single composition.
The generics of Caduet are possible to be released after 11 August, 2018.
Drugs and Companies using AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 29 July, 2004
Treatment: Method of inhibiting cholesterol biosynthesis and treating hypercholesterolemia and method for treating hyperlipidemia; Treatment of hypertension and hyperlipidemia with a single composition
Dosage: TABLET;ORAL
CADUET family patents
